Something is going wrong inside the colons of young Americans, and nobody can fully explain why.
Colorectal cancer — long considered a disease of aging — is now the leading cause of cancer death in men under 50 and the second leading cause in women of the same age group. The numbers are not ambiguous. They are alarming. And they are accelerating.
A generation ago, a 35-year-old showing up at an oncologist’s office with stage III colon cancer would have been a medical curiosity. Today it’s becoming disturbingly routine. The American Cancer Society estimates that in 2025, approximately 153,020 people will be diagnosed with colorectal cancer in the United States. Of those, roughly 20% will be under 55 — a proportion that has nearly doubled since the mid-1990s, according to data the organization published in its Colorectal Cancer Facts & Figures report.
As Business Insider reported, the rise in early-onset colorectal cancer has prompted a broad reassessment of screening guidelines, dietary risk factors, and the very warning signs that younger patients — and their doctors — tend to dismiss.
The question dominating oncology conferences, research labs, and primary care offices alike: What changed?
A Disease Rewriting Its Own Demographics
The trend isn’t subtle. Since the early 1990s, colorectal cancer incidence among adults under 50 has climbed by roughly 1% to 2% per year. Among those aged 20 to 29, the increase has been even steeper — around 2% annually for colon cancer and as much as 3% for rectal cancer, according to the American Cancer Society. Meanwhile, rates among older adults have been declining, thanks largely to widespread colonoscopy screening that catches and removes precancerous polyps before they turn malignant.
The divergence is stark. Screening works. But for decades, guidelines didn’t recommend colonoscopies until age 50. In 2021, the U.S. Preventive Services Task Force lowered the recommended screening age to 45 — a move driven directly by the surge in younger diagnoses. Some researchers argue that even 45 may not be young enough.
Dr. Kimmie Ng, director of the Young-Onset Colorectal Cancer Center at Dana-Farber Cancer Institute, has been at the forefront of studying this phenomenon. In interviews with multiple outlets, she has described the rise as “one of the most pressing questions in cancer research today.” Her center, one of the first dedicated specifically to early-onset disease, sees patients who are often diagnosed at later stages because neither they nor their physicians suspected cancer.
That’s the cruel irony. Young patients frequently experience symptoms for months — sometimes years — before receiving a correct diagnosis. Rectal bleeding gets attributed to hemorrhoids. Abdominal pain is chalked up to irritable bowel syndrome. Fatigue is dismissed as stress. By the time imaging or a scope reveals a tumor, it has often already spread.
Business Insider’s reporting highlighted several warning signs that younger adults should not ignore: persistent changes in bowel habits, blood in the stool, unexplained weight loss, chronic abdominal discomfort, and iron-deficiency anemia without an obvious cause. These symptoms in a 30-year-old deserve the same diagnostic urgency as they would in a 65-year-old. Too often, they don’t get it.
The delays matter. A 2023 study published in the Journal of the National Cancer Institute found that patients diagnosed with early-onset colorectal cancer were significantly more likely to present with advanced-stage disease compared to older patients. Later stage at diagnosis means more aggressive treatment, worse prognoses, and higher mortality.
And mortality is rising. For adults aged 20 to 54, colorectal cancer death rates have increased since the mid-2000s after decades of decline. The American Cancer Society projects roughly 54,000 colorectal cancer deaths in 2025 — a number that would be higher still without the gains made among older, screened populations.
The Search for Causes — and the Frustrating Lack of Answers
Researchers have assembled a long list of suspects. None has been definitively convicted.
Diet sits near the top. The Western dietary pattern — heavy in processed meats, refined grains, added sugars, and low in fiber — has been consistently associated with elevated colorectal cancer risk. Ultra-processed foods, which now constitute more than half of caloric intake for the average American adult, have drawn particular scrutiny. A large-scale study published in The BMJ in 2022 found that higher consumption of ultra-processed foods was associated with increased colorectal cancer risk, especially in men.
But diet alone can’t explain the full picture. Obesity rates have climbed in tandem with early-onset diagnoses, and excess body fat — particularly visceral fat — is a well-established risk factor. Physical inactivity compounds the effect. So does alcohol consumption, which has risen among certain younger demographics even as overall U.S. consumption has plateaued.
Then there’s the gut microbiome. The trillions of bacteria residing in the human colon play a complex role in inflammation, immune regulation, and cellular signaling. Researchers at institutions including the Fred Hutchinson Cancer Center and Memorial Sloan Kettering have been investigating whether shifts in the microbiome — driven by antibiotics, diet, environmental chemicals, or other factors — might be fueling tumor development in younger colons. The science is suggestive but far from settled.
Environmental exposures represent another active area of inquiry. Microplastics, per- and polyfluoroalkyl substances (PFAS), pesticide residues, and endocrine-disrupting chemicals have all been proposed as potential contributors. A study published in early 2025 by researchers at the University of New Mexico found microplastic particles in cancerous colon tissue at concentrations significantly higher than in non-cancerous tissue. The implications are troubling, though causation has not been established.
Genetics plays a role too, but a smaller one than many assume. Hereditary syndromes like Lynch syndrome account for only about 5% to 10% of all colorectal cancers. The vast majority of early-onset cases occur in people with no family history and no known genetic predisposition. Something environmental or behavioral — or some interaction between the two — appears to be driving most of the increase.
Some researchers have pointed to the so-called “birth cohort effect.” People born after 1960, and especially after 1980, carry higher colorectal cancer risk than those born in earlier decades, even after adjusting for known risk factors. This suggests that something about growing up in the late 20th and early 21st centuries — some exposure or combination of exposures encountered early in life — is setting the stage for disease decades later.
What that something is remains elusive.
The frustration is palpable in the research community. “We don’t have a smoking gun,” Dr. Ng told The New York Times in a 2024 interview. “We have a lot of circumstantial evidence pointing in different directions.”
Meanwhile, the cases keep coming. Oncologists report seeing patients in their 20s and 30s with aggressive tumors that defy easy categorization. Some tumors in younger patients exhibit molecular profiles distinct from those found in older patients — more likely to be left-sided, more likely to have certain mutations, and in some cases more resistant to standard chemotherapy regimens. Whether these biological differences reflect a fundamentally different disease process or simply a different host environment is an open question.
The clinical response has been multifaceted. Beyond the lowered screening age, there’s been a push to educate both patients and physicians about the possibility of colorectal cancer in younger adults. The Colorectal Cancer Alliance and other advocacy organizations have launched awareness campaigns targeting people in their 20s, 30s, and 40s — demographics that historically never thought about colon cancer.
Insurance coverage has also shifted. Following the USPSTF recommendation, the Affordable Care Act now requires most insurers to cover screening colonoscopies without cost-sharing for adults starting at age 45. But barriers remain. Many younger adults — particularly those without insurance or with high-deductible plans — delay or forgo screening. And for those under 45 who present with symptoms, getting a timely referral for a colonoscopy can still be a battle.
There’s also a psychological dimension that doesn’t get enough attention. Being diagnosed with colorectal cancer at 32 is a profoundly different experience than being diagnosed at 72. Younger patients face disruptions to careers, fertility, relationships, and identity that older patients may not. The psychosocial toll is enormous, and support systems haven’t fully caught up.
Research funding, too, has lagged behind the scale of the problem. While the National Cancer Institute has increased investment in early-onset colorectal cancer research, advocates argue that spending remains disproportionately low relative to the disease’s growing burden among younger populations. A 2024 analysis by the Colorectal Cancer Alliance found that federal research funding per colorectal cancer death was substantially lower than for breast or prostate cancer.
So where does this leave us? In an uncomfortable place. The data are clear that something is driving a real and sustained increase in colorectal cancer among younger adults. The mechanisms remain poorly understood. Screening helps, but it’s not a complete solution — especially for cancers that develop rapidly between screening intervals or in people below the recommended screening age.
What clinicians and researchers agree on is this: symptoms should not be dismissed based on age alone. A 28-year-old with persistent rectal bleeding deserves a workup, not reassurance. A 40-year-old with unexplained anemia should get a colonoscopy, not just an iron supplement.
The disease is changing. The medical establishment is adapting, but not fast enough for the thousands of young Americans who will be diagnosed this year — many of them at stages where the cancer has already become difficult to treat. Every month of delayed diagnosis can mean the difference between a straightforward surgical cure and years of grueling chemotherapy.
Early-onset colorectal cancer is no longer a statistical anomaly. It’s a public health crisis hiding in plain sight, one that demands the same urgency and resources that have been directed at other cancers affecting younger populations. The warning signs are there — in the data, and in the bodies of patients who are far too young to be fighting this disease.
The question isn’t whether this trend is real. It’s whether we’ll respond to it with the speed it requires.
WebProNews is an iEntry Publication